Delpor will be part of the Innovation Zone, a high profile 6,000 square foot exhibit space dedicated to showcasing 60 NIH and 20 NSF SBIR/STTR awardees.
Delpor expects to meet with several potential partners interested in its implantable drug delivery technologies, and its schizophrenia and diabetes programs.
SAN FRANCISCO, CA, May 31, 2017 –Delpor, Inc. (Delpor), a biotechnology company focused on drug delivery, today announced that it has been selected by the National Institutes of Health (NIH) to exhibit and showcase its technology at the upcoming International Convention of the Biotechnology Innovation Organization (BIO). The Convention will take place in San Diego, CA on June 19-22, 2017. Delpor will be exhibiting at BIO’s “Innovation Zone” along with other innovative companies.
“We are honored to have been selected as one of the companies to exhibit at BIO’s Innovation Zone, and we are looking forward to having fruitful discussions with potential partners” said Tassos Nicolaou, President and CEO of Delpor.
During the conference, Delpor expects to focus on its lead program, DLP-114 (6-month risperidone formulation for schizophrenia maintenance treatment) and on its two key implantable drug delivery technologies (PROZORTM and NANOPORTM).
About Delpor, Inc.
Delpor develops the next generation Drug Delivery Systems that improve the clinical and commercial value of drugs and biopharmaceuticals. The company’s technologies enable the sustained release of drugs through a small non-mechanical subcutaneous implant device. The device is implanted during a 10 minute, simple, in-office, procedure using local anesthetic. Delpor’s device can deliver small & large molecules over several months while maintaining zero-order release pharmacokinetics. The company’s lead products include 3-6 month formulations of Risperidone and Exenatide. Additional information about the company can be found at www.delpor.com.
Delpor’s DLP-114 is a small titanium reservoir designed for subcutaneous implantation and loaded with a proprietary formulation of risperidone. The product is designed to provide a constant therapeutic dose of risperidone each day for a total period of 6 months. Additional features are expected to include reversibility, immediate onset of action, and no accumulation.
To the extent any statements made in this release contain information that is not historical, these statements are essentially forward-looking and are subject to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for new pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, availability of additional intellectual property rights, availability of future financing sources, the regulatory environment and other risks the Company may identify from time to time in the future.
Tassos Nicolaou, President and CEO